查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930134

全球C反應蛋白檢測市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考察、未來預測（2026-2034）

C-Reactive Protein Testing Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 180 Pages | 商品交期: 請詢問到貨日

價格

C反應蛋白（CRP）檢測市場的成長驅動因子

由於慢性病盛行率的上升、即時檢測（POC）的廣泛應用以及人們對CRP作為發炎標記物作用的認識不斷提高，全球C反應蛋白（CRP）檢測市場預計將穩步成長。根據Fortune Business Insights預測，該市場規模在2025年達到25.5億美元，預計2026年成長至26.9億美元，到2034年達到39.5億美元，預測期內年複合成長率（CAGR）為4.9%。到2025年，北美以 34.5%的市場佔有率引領市場，這主要得益於高疾病負擔、先進的醫療基礎設施以及對 CRP 即時檢測日益成長的需求。

CRP 是一種非特異性發炎標記物，在預測心血管風險（包括心臟病發作和中風）方面發揮重要作用。它也用於診斷癌症、類風濕性關節炎和其他自體免疫疾病等慢性疾病。 CRP 檢測設備和試劑盒（包括即時檢測解決方案）的技術進步進一步推動市場成長。

市場動態

驅動因素

心血管疾病、癌症和自體免疫疾病等慢性疾病的日益普遍推動對 CRP 檢測的需求。根據美國疾病管制與預防中心（CDC）2022年的資料，美國約有 2,010萬成年人患有冠狀動脈疾病，每年約有 80.5萬例心肌梗塞。患者群體不斷擴大以及對預防保健的日益重視，正推動著 CRP 檢測在全球的普及。

另一個主要驅動因素是即時檢測（POC）CRP 檢測的發展，這有助於臨床醫生減少抗生素處方並提高診斷效率。例如，發表在《英國全科醫學雜誌》（2022）上的一項研究強調了使用 CRP POC 檢測來診斷急性呼吸道感染，最大限度地減少不必要的抗生素使用。 Bloom Diagnostics 和 LumiraDx 等公司已推出先進的POC CRP 檢測，以滿足這一日益成長的需求。

趨勢

市場對技術先進的檢測試劑盒和設備越來越感興趣。免疫比濁法檢測在2026年將佔據市場主導地位，市場佔有率高達75.09%，主要得益於產品的廣泛應用和臨床實驗室的廣泛採用。高敏感性C反應蛋白（hs-CRP）檢測在心血管風險評估中日益受到關注。此外，社區醫療機構中即時檢測（POC）的日益普及預計將進一步推動市場成長。

限制因子

CRP是一種非特異性發炎標記物，因此其作為獨立診斷檢測的應用受到限制。冠狀動脈CT血管攝影、心電圖（ECG）和運動負荷試驗等替代診斷方法能夠提供更準確、更具疾病特異性的結果。這些替代方法的出現可能會在一定程度上減緩CRP檢測的普及。

市場區隔

依產品分類：市場分為試劑和試劑盒以及設備。試劑和試劑盒市場主要受檢測量大和Abbott、LumiraDx等大型公司強大的產品陣容推動，預計到2026年將佔據73.61%的市場佔有率。由於創新型設備（例如2022年獲得美國FDA批准的ProciseDx設備）的監管批准不斷增加，預計設備市場也將成長。

依檢測類型劃分：市場分為免疫比濁法、酵素連結免疫吸附試驗（ELISA）、化學發光免疫分析法（CLIA）及其他方法。免疫比濁法因其易用性和廣泛應用而佔據市場主導地位，而ELISA和CLIA檢測方法也呈現穩定成長，尤其是在慢性病檢測方面。

依檢測範圍劃分：到2026年，傳統C反應蛋白（CRP）檢測將佔據89.96%的市場佔有率，主要用於監測慢性病和自體免疫疾病。高敏C反應蛋白檢測日益用於心血管風險評估。

依檢測方式劃分：實驗室檢測憑藉其先進且全面的分析能力，將在2026年佔據75.84%的市場佔有率，保持領先地位。同時，即時檢測（POC）預計將在資源匱乏地區和基層醫療機構實現顯著成長。

依最終用戶劃分：由於慢性病管理檢測數量的增加，診斷實驗室將引領市場。同時，由於住院人數和臨床需求的增加，醫院和診所預計將強勁成長。

區域洞察

  • 北美：8.8億美元（2025年），8.5億美元（2026年）。美國市場的成長動力來自慢性病負擔、創新和臨床研究。
  • 歐洲：英國：1.02億美元，德國：1.08億美元（2026年）。監管審批、CE認證產品以及自體免疫疾病監測領域日益成長的應用將推動市場成長。
  • 亞太地區：日本：1.5億美元，中國：2.2億美元，印度：1.1億美元（2026年）。主要驅動因素包括慢性病流行、公共衛生措施以及策略夥伴關係，例如FIND-SD生物感測器合作計畫。
  • 拉丁美洲、中東和非洲：由於醫療基礎設施的改善和快速診斷測試的廣泛應用，預計將實現溫和成長。

主要行業參與者

該市場的主要公司包括Abbott、F. Hoffmann-La Roche Ltd.、Siemens Healthcare、Quest Diagnostics、Thermo Fisher Scientific、Merck KGaA、Getein Biotech、Randox Laboratories、Boditech Med、LumiraDx。市場參與者專注於研發、新產品發布以及拓展即時檢測（POC）產品線。例如，Abbott於2016年收購了Alere Inc.，擴展了其即時檢測產品組合。

值得注意的進展包括：Siemens的CardioPhase hs-CRP 檢測獲得 FDA 批准（2022年 12月），以及與 Boditech Med 就其進入北美市場簽署諒解備忘錄（2022年 3月）。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 主要國家和地區主要慢性病盛行率
  • C反應蛋白檢測技術進展
  • 新產品發布
  • 關鍵產業趨勢：併購、業務合作等
  • 新冠疫情對市場的影響

第5章 全球市場C反應蛋白檢測市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依產品分類
    • 試劑和試劑盒
    • 儀器
  • 市場分析、洞察與預測：依檢測類型分類
    • 化學發光免疫分析法（CLIA）
    • 酵素連結免疫吸附試驗（ELISA）
    • 免疫比濁法
    • 其他
  • 市場分析、洞察與預測：依檢測範圍分類
    • 常規CRP
    • 高敏感性CRP
  • 市場分析、洞察與預測：依操作環境分類
    • 實驗室檢測
    • 即時偵測（POC）偵測
  • 市場分析、洞察與預測：依最終用戶劃分
    • 醫院和診所
    • 診斷實驗室
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美 C 反應蛋白檢測市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲 C 反應蛋白檢測市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家

第8章 亞太地區 C 反應蛋白檢測市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太其他地區

第9章 拉丁美洲 C 反應蛋白檢測市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第10章 中東與非洲 C 反應蛋白檢測市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • GCC國家
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 全球市場佔有率分析（2025）
  • 公司簡介
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare Private Limited
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Getein Biotech, Inc.
  • Randox Laboratories Ltd.
  • BODITECH MED, INC.
  • LumiraDx
Product Code: FBI107164

Growth Factors of C-reactive protein (CRP) testing Market

The global C-reactive protein (CRP) testing market is projected to witness steady growth due to the rising prevalence of chronic diseases, increasing adoption of point-of-care (POC) testing, and growing awareness about the role of CRP as an inflammation marker. According to Fortune Business Insights, the market was valued at USD 2.55 billion in 2025, expected to grow to USD 2.69 billion in 2026, and is forecasted to reach USD 3.95 billion by 2034, registering a CAGR of 4.9% during the forecast period. North America dominated the market in 2025 with a share of 34.5%, driven by high disease burden, advanced healthcare infrastructure, and growing preference for CRP point-of-care tests.

CRP is a non-specific marker of inflammation and plays a critical role in predicting cardiovascular risks, including heart attack and stroke. It is also used in diagnosing chronic conditions such as cancer, rheumatoid arthritis, and other autoimmune diseases. The market growth is further supported by technological advancements in CRP testing instruments and kits, including POC solutions.

Market Dynamics

Drivers

The increasing prevalence of chronic diseases, such as cardiovascular diseases, cancer, and autoimmune disorders, has driven the demand for CRP testing. According to CDC data from 2022, approximately 20.1 million adults in the U.S. suffer from coronary artery disease, with an estimated 805,000 heart attacks occurring annually. The rising patient population and growing focus on preventive healthcare have fueled the adoption of CRP testing globally.

Another major driver is the development of point-of-care CRP tests, which aid clinicians in reducing antibiotic prescriptions and improving diagnostic efficiency. For instance, research published in the British Journal of General Practice (2022) highlighted the use of CRP POC testing for acute respiratory infections to minimize unnecessary antibiotic use. Companies such as Bloom Diagnostics and LumiraDx are launching advanced POC CRP tests to address this growing need.

Trends

The market is witnessing a growing focus on technologically advanced testing kits and instruments. The immunoturbidimetric assay segment dominated the market in 2026 with a 75.09% share, due to widespread product availability and strong adoption in clinical laboratories. High-sensitivity CRP (hs-CRP) testing is gaining traction for cardiovascular risk assessment. Additionally, the increasing use of POC tests in community healthcare settings is expected to drive growth further.

Restraints

CRP is a non-specific inflammation marker, which limits its use as a standalone diagnostic test. Alternative diagnostics, such as coronary CT angiography, electrocardiography (ECG), and stress tests, provide more accurate disease-specific results. The availability of these alternatives may slow the adoption of CRP tests to some extent.

Market Segmentation

By Product: The market is divided into reagents & kits and instruments. Reagents & kits dominated with a 73.61% share in 2026, driven by high testing volumes and strong offerings from key players like Abbott and LumiraDx. The instruments segment is expected to grow due to increasing regulatory approvals for innovative devices, such as the ProciseDx instrument approved by the U.S. FDA in 2022.

By Assay Type: The market is segmented into immunoturbidimetric assay, ELISA, CLIA, and others. Immunoturbidimetric assays lead due to ease of use and widespread adoption, while ELISA and CLIA-based assays are steadily growing, particularly for chronic disease detection.

By Detection Range: Conventional CRP dominated with an 89.96% share in 2026, primarily for chronic and autoimmune disease monitoring. High-sensitivity CRP tests are increasingly used for cardiovascular risk assessment.

By Setting: Laboratory testing led with 75.84% share in 2026, attributed to precise and comprehensive analysis. POC testing is expected to grow significantly in resource-limited or primary care settings.

By End-User: Diagnostic laboratories dominate due to the increasing number of tests for chronic disease management, while hospitals and clinics are expected to witness strong growth due to rising hospitalizations and clinical demand.

Regional Insights

  • North America: USD 0.88B (2025), USD 0.85B (2026); dominated by U.S. chronic disease burden, innovation, and clinical research.
  • Europe: UK USD 0.12B, Germany USD 0.18B (2026); growth supported by regulatory approvals, CE-marked products, and rising adoption for autoimmune disease monitoring.
  • Asia Pacific: Japan USD 0.15B, China USD 0.22B, India USD 0.11B (2026); driven by chronic disease prevalence, public health initiatives, and strategic partnerships such as FIND-SD Biosensor collaborations.
  • Latin America & Middle East/Africa: Moderate growth due to improving healthcare infrastructure and adoption of rapid diagnostic tests.

Key Industry Players

Prominent companies in the market include Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthcare, Quest Diagnostics, Thermo Fisher Scientific, Merck KGaA, Getein Biotech, Randox Laboratories, Boditech Med, and LumiraDx. Market players are focusing on research and development, new product launches, and expanding POC offerings. For instance, Abbott's acquisition of Alere Inc. in 2016 expanded its POC testing portfolio.

Notable developments include Siemens FDA clearance for CardioPhase hs-CRP test (Dec 2022) and Boditech Med MoU for North American market entry (Mar 2022).

Conclusion

The global C-reactive protein testing market is projected to grow from USD 2.55 billion in 2025 to USD 3.95 billion by 2034, supported by rising chronic disease prevalence, increasing adoption of POC tests, and continuous innovation in assay technologies. Despite limitations due to alternative diagnostics, CRP testing remains a vital tool for inflammation monitoring, cardiovascular risk prediction, and improving patient management worldwide.

Segmentation By Product, Assay Type, Detection Range, Setting, End User, and Region

By Product * Reagents & Kits

  • Instruments

By Assay Type * Chemiluminescence Immunoassay (CLIA)

  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunoturbidimetric Assay
  • Others

By Detection Range * Conventional CRP

  • hs-CRP

By Setting

Laboratory Testing

  • Point-of-Care (POC) Testing

By End User * Hospitals & Clinics

  • Diagnostic Laboratories
  • Others

By Region * North America (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country)

    • U.S.
    • Canada
  • Europe (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Chronic Diseases, By Key Countries/Regions
  • 4.2. Technological Advancements in C-Reactive Protein Testing
  • 4.3. New Product Launches
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Reagents & Kits
    • 5.1.2. Instruments
  • 5.2. Market Analysis, Insights and Forecast - By Assay Type
    • 5.2.1. Chemiluminescence Immunoassay (CLIA)
    • 5.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 5.2.3. Immunoturbidimetric Assay
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Detection Range
    • 5.3.1. Conventional CRP
    • 5.3.2. Hs-CRP
  • 5.4. Market Analysis, Insights and Forecast - By Setting
    • 5.4.1. Laboratory Testing
    • 5.4.2. Point-of-Care (POC) Testing
  • 5.5. Market Analysis, Insights and Forecast - By End-User
    • 5.5.1. Hospitals & Clinics
    • 5.5.2. Diagnostic Laboratories
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Reagents & Kits
    • 6.1.2. Instruments
  • 6.2. Market Analysis, Insights and Forecast - By Assay Type
    • 6.2.1. Chemiluminescence Immunoassay (CLIA)
    • 6.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 6.2.3. Immunoturbidimetric Assay
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Detection Range
    • 6.3.1. Conventional CRP
    • 6.3.2. Hs-CRP
  • 6.4. Market Analysis, Insights and Forecast - By Setting
    • 6.4.1. Laboratory Testing
    • 6.4.2. Point-of-Care (POC) Testing
  • 6.5. Market Analysis, Insights and Forecast - By End-User
    • 6.5.1. Hospitals & Clinics
    • 6.5.2. Diagnostic Laboratories
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Reagents & Kits
    • 7.1.2. Instruments
  • 7.2. Market Analysis, Insights and Forecast - By Assay Type
    • 7.2.1. Chemiluminescence Immunoassay (CLIA)
    • 7.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 7.2.3. Immunoturbidimetric Assay
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Detection Range
    • 7.3.1. Conventional CRP
    • 7.3.2. Hs-CRP
  • 7.4. Market Analysis, Insights and Forecast - By Setting
    • 7.4.1. Laboratory Testing
    • 7.4.2. Point-of-Care (POC) Testing
  • 7.5. Market Analysis, Insights and Forecast - By End-User
    • 7.5.1. Hospitals & Clinics
    • 7.5.2. Diagnostic Laboratories
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Rest of Europe

8. Asia Pacific C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Reagents & Kits
    • 8.1.2. Instruments
  • 8.2. Market Analysis, Insights and Forecast - By Assay Type
    • 8.2.1. Chemiluminescence Immunoassay (CLIA)
    • 8.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 8.2.3. Immunoturbidimetric Assay
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Detection Range
    • 8.3.1. Conventional CRP
    • 8.3.2. Hs-CRP
  • 8.4. Market Analysis, Insights and Forecast - By Setting
    • 8.4.1. Laboratory Testing
    • 8.4.2. Point-of-Care (POC) Testing
  • 8.5. Market Analysis, Insights and Forecast - By End-User
    • 8.5.1. Hospitals & Clinics
    • 8.5.2. Diagnostic Laboratories
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. Australia
    • 8.6.5. Rest of Asia Pacific

9. Latin America C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Reagents & Kits
    • 9.1.2. Instruments
  • 9.2. Market Analysis, Insights and Forecast - By Assay Type
    • 9.2.1. Chemiluminescence Immunoassay (CLIA)
    • 9.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 9.2.3. Immunoturbidimetric Assay
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Detection Range
    • 9.3.1. Conventional CRP
    • 9.3.2. Hs-CRP
  • 9.4. Market Analysis, Insights and Forecast - By Setting
    • 9.4.1. Laboratory Testing
    • 9.4.2. Point-of-Care (POC) Testing
  • 9.5. Market Analysis, Insights and Forecast - By End-User
    • 9.5.1. Hospitals & Clinics
    • 9.5.2. Diagnostic Laboratories
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa C-Reactive Protein Testing Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Reagents & Kits
    • 10.1.2. Instruments
  • 10.2. Market Analysis, Insights and Forecast - By Assay Type
    • 10.2.1. Chemiluminescence Immunoassay (CLIA)
    • 10.2.2. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 10.2.3. Immunoturbidimetric Assay
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Detection Range
    • 10.3.1. Conventional CRP
    • 10.3.2. Hs-CRP
  • 10.4. Market Analysis, Insights and Forecast - By Setting
    • 10.4.1. Laboratory Testing
    • 10.4.2. Point-of-Care (POC) Testing
  • 10.5. Market Analysis, Insights and Forecast - By End-User
    • 10.5.1. Hospitals & Clinics
    • 10.5.2. Diagnostic Laboratories
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
    • 11.2.1. Abbott
      • 11.2.1.1. Overview,
      • 11.2.1.2. Product,
      • 11.2.1.3. SWOT Analysis,
      • 11.2.1.4. Recent Developments,
      • 11.2.1.5. Strategies,
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. F. Hoffmann-La Roche Ltd.
      • 11.2.2.1. Overview,
      • 11.2.2.2. Product,
      • 11.2.2.3. SWOT Analysis,
      • 11.2.2.4. Recent Developments,
      • 11.2.2.5. Strategies,
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Siemens Healthcare Private Limited
      • 11.2.3.1. Overview,
      • 11.2.3.2. Product,
      • 11.2.3.3. SWOT Analysis,
      • 11.2.3.4. Recent Developments,
      • 11.2.3.5. Strategies,
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Quest Diagnostics Incorporated
      • 11.2.4.1. Overview,
      • 11.2.4.2. Product,
      • 11.2.4.3. SWOT Analysis,
      • 11.2.4.4. Recent Developments,
      • 11.2.4.5. Strategies,
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Thermo Fisher Scientific, Inc.
      • 11.2.5.1. Overview,
      • 11.2.5.2. Product,
      • 11.2.5.3. SWOT Analysis,
      • 11.2.5.4. Recent Developments,
      • 11.2.5.5. Strategies,
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. Merck KGaA
      • 11.2.6.1. Overview,
      • 11.2.6.2. Product,
      • 11.2.6.3. SWOT Analysis,
      • 11.2.6.4. Recent Developments,
      • 11.2.6.5. Strategies,
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. Getein Biotech, Inc.
      • 11.2.7.1. Overview,
      • 11.2.7.2. Product,
      • 11.2.7.3. SWOT Analysis,
      • 11.2.7.4. Recent Developments,
      • 11.2.7.5. Strategies,
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Randox Laboratories Ltd.
      • 11.2.8.1. Overview,
      • 11.2.8.2. Product,
      • 11.2.8.3. SWOT Analysis,
      • 11.2.8.4. Recent Developments,
      • 11.2.8.5. Strategies,
      • 11.2.8.6. financials (Based on Availability)
    • 11.2.9. BODITECH MED, INC.
      • 11.2.9.1. Overview,
      • 11.2.9.2. Product,
      • 11.2.9.3. SWOT Analysis,
      • 11.2.9.4. Recent Developments,
      • 11.2.9.5. Strategies,
      • 11.2.9.6. financials (Based on Availability)
    • 11.2.10. LumiraDx
      • 11.2.10.1. Overview,
      • 11.2.10.2. Product,
      • 11.2.10.3. SWOT Analysis,
      • 11.2.10.4. Recent Developments,
      • 11.2.10.5. Strategies,
      • 11.2.10.6. financials (Based on Availability)

List of Tables

  • Table 1: Global C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 2: Global C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Assay Type, 2021-2034
  • Table 3: Global C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Detection Range, 2021-2034
  • Table 4: Global C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 5: Global C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 6: Global C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 8: North America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Assay Type, 2021-2034
  • Table 9: North America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Detection Range, 2021-2034
  • Table 10: North America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 11: North America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 12: North America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: Europe C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 14: Europe C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Assay Type, 2021-2034
  • Table 15: Europe C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Detection Range, 2021-2034
  • Table 16: Europe C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 17: Europe C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 18: Europe C-Reactive Protein Testing Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 20: Asia Pacific C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Assay Type, 2021-2034
  • Table 21: Asia Pacific C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Detection Range, 2021-2034
  • Table 22: Asia Pacific C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 23: Asia Pacific C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 24: Asia Pacific C-Reactive Protein Testing Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: Latin America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 26: Latin America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Assay Type, 2021-2034
  • Table 27: Latin America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Detection Range, 2021-2034
  • Table 28: Latin America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 29: Latin America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 30: Latin America C-Reactive Protein Testing Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 32: Middle East & Africa C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Assay Type, 2021-2034
  • Table 33: Middle East & Africa C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Detection Range, 2021-2034
  • Table 34: Middle East & Africa C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 35: Middle East & Africa C-Reactive Protein Testing Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 36: Middle East & Africa C-Reactive Protein Testing Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global C-Reactive Protein Testing Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global C-Reactive Protein Testing Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global C-Reactive Protein Testing Market Value Share (%), by Assay Type, 2025 & 2034
  • Figure 4: Global C-Reactive Protein Testing Market Value Share (%), by Detection Range, 2025 & 2034
  • Figure 5: Global C-Reactive Protein Testing Market Value Share (%), by Setting, 2025 & 2034
  • Figure 6: Global C-Reactive Protein Testing Market Value Share (%), by End-User, 2025 & 2034
  • Figure 7: Global C-Reactive Protein Testing Market Value (USD billion), by Region, 2025 & 2034
  • Figure 8: North America C-Reactive Protein Testing Market Value (USD billion), by Product, 2025 & 2034
  • Figure 9: North America C-Reactive Protein Testing Market Value Share (%), by Product, 2025
  • Figure 10: North America C-Reactive Protein Testing Market Value (USD billion), by Assay Type, 2025 & 2034
  • Figure 11: North America C-Reactive Protein Testing Market Value Share (%), by Assay Type, 2025
  • Figure 12: North America C-Reactive Protein Testing Market Value (USD billion), by Detection Range, 2025 & 2034
  • Figure 13: North America C-Reactive Protein Testing Market Value Share (%), by Detection Range, 2025
  • Figure 14: North America C-Reactive Protein Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 15: North America C-Reactive Protein Testing Market Value Share (%), by Setting, 2025
  • Figure 16: North America C-Reactive Protein Testing Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 17: North America C-Reactive Protein Testing Market Value Share (%), by End-User, 2025
  • Figure 18: North America C-Reactive Protein Testing Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America C-Reactive Protein Testing Market Value Share (%), By Country, 2025
  • Figure 20: Europe C-Reactive Protein Testing Market Value (USD billion), by Product, 2025 & 2034
  • Figure 21: Europe C-Reactive Protein Testing Market Value Share (%), by Product, 2025
  • Figure 22: Europe C-Reactive Protein Testing Market Value (USD billion), by Assay Type, 2025 & 2034
  • Figure 23: Europe C-Reactive Protein Testing Market Value Share (%), by Assay Type, 2025
  • Figure 24: Europe C-Reactive Protein Testing Market Value (USD billion), by Detection Range, 2025 & 2034
  • Figure 25: Europe C-Reactive Protein Testing Market Value Share (%), by Detection Range, 2025
  • Figure 26: Europe C-Reactive Protein Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 27: Europe C-Reactive Protein Testing Market Value Share (%), by Setting, 2025
  • Figure 28: Europe C-Reactive Protein Testing Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 29: Europe C-Reactive Protein Testing Market Value Share (%), by End-User, 2025
  • Figure 30: Europe C-Reactive Protein Testing Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe C-Reactive Protein Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific C-Reactive Protein Testing Market Value (USD billion), by Product, 2025 & 2034
  • Figure 33: Asia Pacific C-Reactive Protein Testing Market Value Share (%), by Product, 2025
  • Figure 34: Asia Pacific C-Reactive Protein Testing Market Value (USD billion), by Assay Type, 2025 & 2034
  • Figure 35: Asia Pacific C-Reactive Protein Testing Market Value Share (%), by Assay Type, 2025
  • Figure 36: Asia Pacific C-Reactive Protein Testing Market Value (USD billion), by Detection Range, 2025 & 2034
  • Figure 37: Asia Pacific C-Reactive Protein Testing Market Value Share (%), by Detection Range, 2025
  • Figure 38: Asia Pacific C-Reactive Protein Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 39: Asia Pacific C-Reactive Protein Testing Market Value Share (%), by Setting, 2025
  • Figure 40: Asia Pacific C-Reactive Protein Testing Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 41: Asia Pacific C-Reactive Protein Testing Market Value Share (%), by End-User, 2025
  • Figure 42: Asia Pacific C-Reactive Protein Testing Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific C-Reactive Protein Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America C-Reactive Protein Testing Market Value (USD billion), by Product, 2025 & 2034
  • Figure 45: Latin America C-Reactive Protein Testing Market Value Share (%), by Product, 2025
  • Figure 46: Latin America C-Reactive Protein Testing Market Value (USD billion), by Assay Type, 2025 & 2034
  • Figure 47: Latin America C-Reactive Protein Testing Market Value Share (%), by Assay Type, 2025
  • Figure 48: Latin America C-Reactive Protein Testing Market Value (USD billion), by Detection Range, 2025 & 2034
  • Figure 49: Latin America C-Reactive Protein Testing Market Value Share (%), by Detection Range, 2025
  • Figure 50: Latin America C-Reactive Protein Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 51: Latin America C-Reactive Protein Testing Market Value Share (%), by Setting, 2025
  • Figure 52: Latin America C-Reactive Protein Testing Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 53: Latin America C-Reactive Protein Testing Market Value Share (%), by End-User, 2025
  • Figure 54: Latin America C-Reactive Protein Testing Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America C-Reactive Protein Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa C-Reactive Protein Testing Market Value (USD billion), by Product, 2025 & 2034
  • Figure 57: Middle East & Africa C-Reactive Protein Testing Market Value Share (%), by Product, 2025
  • Figure 58: Middle East & Africa C-Reactive Protein Testing Market Value (USD billion), by Assay Type, 2025 & 2034
  • Figure 59: Middle East & Africa C-Reactive Protein Testing Market Value Share (%), by Assay Type, 2025
  • Figure 60: Middle East & Africa C-Reactive Protein Testing Market Value (USD billion), by Detection Range, 2025 & 2034
  • Figure 61: Middle East & Africa C-Reactive Protein Testing Market Value Share (%), by Detection Range, 2025
  • Figure 62: Middle East & Africa C-Reactive Protein Testing Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 63: Middle East & Africa C-Reactive Protein Testing Market Value Share (%), by Setting, 2025
  • Figure 64: Middle East & Africa C-Reactive Protein Testing Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 65: Middle East & Africa C-Reactive Protein Testing Market Value Share (%), by End-User, 2025
  • Figure 66: Middle East & Africa C-Reactive Protein Testing Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa C-Reactive Protein Testing Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global C-Reactive Protein Testing Market Share (%), By Company, 2025